2020
CONTINUING EDUCATION INFORMATION

VIRTUAL HFSA 2020
ANNUAL SCIENTIFIC MEETING
WHERE HEART FAILURE TEAMS GATHER

September 30 - October 6, 2020
virtual.hfsa.org

hfsa.org/annualscientificmeeting
2020 Program Committee

Co-Chairs
Javed Butler, MD, MPH, MBA
Sandra B. Dunbar, RN, PhD
Peter Liu, MD, FRCPC
J Herb Patterson, PharmD, FHFA

Program Committee
Jeffrey Alexis, MD
Larry Allen, MD MS, FHFA
Arvind Bhimaraj, MD
Hong Chen, MD
Julie Creaser, RN, MSN
Anita Deswal, MD, MPH, FHFA
Robert Didomenico, PharmD
Katherine E. Di Palo, PharmD, BCACP, BCGP
Eiran Gorodeski, MD MPH
Justin Grodin, MD MPH
Doug Jennings, PharmD
Peggy Kirkwood, RN MSN
Liviu Klein, MD
Walter J. Koch, PhD
Alanna Morris, MD, MSc, FHFA
Srinivas Murali, MD
Gurusher Panjrat, MD (MBBS)
Marian R. Piano, PhD, RN, FAHA, FAAN
Bunny Pozehl, PhD, RN
Julie Rosenthal, MD
Douglas Sawyer, MD, PhD
Kristen Sethares, PhD, RN, CNE, FAHA
Palak Shah, MD MS, FHFA
Marc Simon, MD
Amanda Vest, MD FHFA (MBBS)
Joseph C. Wu, MD, PhD
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians**

HFSA designates this live activity for a maximum of 60.05 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 12.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

**Nurses**

This educational activity is approved for continuing nursing education (CNE) units by the Heart Failure Society of American, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 60.05 contact hours (which includes 16.00 hours of nursing pharmacology. See details below).

**Pharmacology Hours for Nurses**

For Nurses who require pharmacology hours for their certification or licensure renewal, this year the HFSA Annual meeting offers opportunities to accrue 16.00 hours. Here the session offering credit hours:

**Wednesday, September 30**

6:00 PM – 7:00 PM
COVID-19: Lessons Learned in HF and Living with the New Normal
Credit Hour(s): 0.25

6:00 PM – 7:00 PM
To Right a Wrong in HF
Credit Hour(s): 0.50

7:15 PM – 8:15 PM
Beyond Socioeconomic & Access To Care: The Clinical Imperative for Understanding Racial HF Differences and Disparities
Credit Hour(s): 0.25

7:15 PM – 8:15 PM
Heart Meets Kidney
Credit Hour(s): 0.75

**Thursday, October 1**

6:00 PM – 7:00 PM
Supporting the HF Workforce: Optimizing Physical and Mental Wellness Among HF Providers
Credit Hour(s): 0.25

7:15 PM – 8:15 PM
HF and the End of Life—Opportunities for Innovation and Collaboration at the Intersection of Cardiology and Palliative Care
Credit Hour(s): 0.25

Friday, October 2

6:00 PM – 7:00 PM
HF Hospitalizations and Transitions of Care: It Takes A Village
Credit Hour(s): 0.25

**Saturday, October 3**

11:45 AM – 1:15 PM
Management of HF in Rural/Frontier Areas: Challenges and Potential Solutions for Clinical Practice and Research
Credit Hour(s): 0.50

11:45 AM – 1:15 PM
Myocarditis: Management Update (Joint Session w/ Myocarditis Foundation)
Credit Hour(s): 0.75

3:00 PM – 4:15 PM
Unfolding Developments in the Care of Patients with TTR Cardiac Amyloidosis
Credit Hour(s): 0.75
CE Credit Information

**Pharmacology Hours for Nurses Continued (Saturday, October 3)**

3:00 PM – 4:15 PM
Dangerous Liaisons in Pulmonary Hypertension
Credit Hour(s): 0.50

3:00 PM – 4:15 PM
Structural Interventions for A Failing Heart - A Partnership Between Interventional and HF Cardiologists
Credit Hour(s): 0.50

4:30 PM – 5:30 PM
Advances in the Treatment of Monogenic Cardiomyopathies
Credit Hour(s): 0.25

3:00 PM – 4:15 PM
Dangerous Liaisons in Pulmonary Hypertension
Credit Hour(s): 0.50

4:30 PM – 5:30 PM
Structural Interventions for A Failing Heart - A Partnership Between Interventional and HF Cardiologists
Credit Hour(s): 0.50

4:30 PM – 5:30 PM
Advances in the Treatment of Monogenic Cardiomyopathies
Credit Hour(s): 0.25

**Pharmacology Hours for Pharmacists (Saturday, October 3)**

3:00 PM – 4:15 PM
Understanding HF with Recovered Ejection Fraction
Credit Hour(s): 0.75

4:30 PM – 5:45 PM
Integrated Omics in HF: Precision Medicine Highlights for HF Clinicians and Scientists
Credit Hour(s): 0.25

4:30 PM – 5:45 PM
The Intersection of Cardio-Oncology and Advanced HF: From Stage A to D
Credit Hour(s): 0.75

**Sunday, October 4**

10:00 AM – 11:30 AM
New Data and Learnings from VICTORIA Trial
Credit Hour(s): 1.00

10:00 AM – 11:30 AM
Cardiogenic Shock in 2020: Evolving Definitions, Devices, and Delivery
Credit Hour(s): 0.50

11:45 AM – 1:15 PM
DAPA-HF - One Year On
Credit Hour(s): 1.50

11:45 AM – 1:15 PM
Cardiac Cachexia: Mechanisms, Measuring Muscle, and Managing Malnutrition
Credit Hour(s): 0.50

11:45 AM – 1:15 PM
Targeting Therapy for HFpEF
Credit Hour(s): 0.75

**Monday, October 5**

6:00 PM – 7:00 PM
Late Breaking Clinical Trials II
Credit Hour(s): 0.25

**Tuesday, October 6**

6:00 PM – 7:00 PM
How to Manage Cardiovascular Complications During Pregnancy
Credit Hour(s): 0.75

The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This event is accredited for 34.75 contact hours of knowledge-based CPE. Pharmacist participants may earn up to 34.75 hours of knowledge-based CPE. To earn credit, participants must complete the online evaluation for each presentation attended and submit their NABP ID and DOB (MMDD). Once evaluations are completed, CPE will be uploaded to CPE monitor within 60 days of the close of the activity. Pharmacist must fill out evaluation to claim credit by 11:59 PM EST on Friday, November 20, 2020.
CE Credit Information

(Pharmacist Hours Continued)

**Wednesday, September 30, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>ACPE UAN</th>
<th>Hours</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td>COVID-19: Lessons Learned in HF and Living with the New Normal</td>
<td>JA4008267-0000-20-001-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>To Right A Wrong in Heart Failure</td>
<td>JA4008267-0000-20-002-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Beyond Socioeconomic &amp; Access To Care: The Clinical Imperative for Understanding Racial HF Differences and Disparities</td>
<td>JA4008267-0000-20-003-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Heart Meets Kidney</td>
<td>JA4008267-0000-20-004-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
</tbody>
</table>

**Thursday, October 1, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>ACPE UAN</th>
<th>Hours</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td>Update on Medical Treatment Strategies in HF</td>
<td>JA4008267-0000-20-005-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Supporting the HF Workforce: Optimizing Physical and Mental Wellness Among HF Providers</td>
<td>JA4008267-0000-20-006-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>HF and the End of Life – Opportunities for Innovation and Collaboration at the Intersection of Cardiology and Palliative Care</td>
<td>JA4008267-0000-20-007-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
</tbody>
</table>

**Friday, October 2, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>ACPE UAN</th>
<th>Hours</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td>2020 and Beyond: Background Medical Therapy for Clinical Trials</td>
<td>JA4008267-0000-20-008-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Contemporary Challenges In Heart Transplantation: A New Decade, New Opportunities</td>
<td>JA4008267-0000-20-009-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>HF Hospitalizations and Transitions of Care: It Takes A Village</td>
<td>JA4008267-0000-20-010-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
</tbody>
</table>

**Saturday, October 3, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>ACPE UAN</th>
<th>Hours</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 AM</td>
<td>Management of HF in Rural/ Frontier Areas: Challenges and Potential Solutions for Clinical Practice and Research</td>
<td>JA4008267-0000-20-011-H04-P</td>
<td>1.5</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>11:45 AM</td>
<td>Myocarditis: Management Update</td>
<td>JA4008267-0000-20-012-H04-P</td>
<td>1.5</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Unfolding Developments in the Care of Patients with TTR Cardiac Amyloidosis</td>
<td>JA4008267-0000-20-013-H04-P</td>
<td>1.25</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Dangerous Liaisons in Pulmonary Hypertension</td>
<td>JA4008267-0000-20-014-H04-P</td>
<td>1.25</td>
<td>knowledge-based</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Advances in the Treatment of Monogenic Cardiomyopathies</td>
<td>JA4008267-0000-20-015-H04-P</td>
<td>1.0</td>
<td>knowledge-based</td>
</tr>
</tbody>
</table>
CE Credit Information

(Pharmacist Hours Continued (Saturday, October 3))

4:30 PM – 5:30 PM
Traversing Care and Guidelines for Patients with HF and Multiple Co-Morbidities
ACPE UAN: JA4008267-0000-20-016-H04-P
(1.0 contact hours – knowledge-based)

6:00 PM – 7:00 PM
Knowing it When you See it: Defining Congestion and Decongestion ACPE UAN: JA4008267-0000-20-017-H04-P
(1.0 contact hours – knowledge-based)

6:00 PM – 7:00 PM
When Social Determinants of Health Collide with HF Care and Treatment Decisions
ACPE UAN: JA4008267-0000-20-018-H04-P
(1.0 contact hours – knowledge-based)

Sunday, October 4, 2020

10:00 AM – 11:30 AM
Cardiogenic Shock in 2020: Evolving Definitions, Devices, and Delivery
ACPE UAN: JA4008267-0000-20-019-H04-P
(1.5 contact hours – knowledge-based)

11:45 AM – 1:15 PM
Women in HF Career Forum
ACPE UAN: JA4008267-0000-20-020-H04-P
(1.5 contact hours – knowledge-based)

11:45 AM – 1:15 PM
Cardiac Cachexia: Mechanisms, Measuring Muscle, and Managing Malnutrition
ACPE UAN: JA4008267-0000-20-021-H04-P
(1.5 contact hours – knowledge-based)

3:00 PM – 4:15 PM
Targeting Therapy for HFpEF
ACPE UAN: JA4008267-0000-20-022-H04-P
(1.5 contact hours – knowledge-based)

3:00 PM – 4:15 PM
Women and Gender Influences in HF
ACPE UAN: JA4008267-0000-20-023-H04-P
(1.5 contact hours – knowledge-based)

4:30 PM – 5:45 PM
Understanding HF with Recovered Ejection Fraction
ACPE UAN: JA4008267-0000-20-024-H04-P
(1.25 contact hours – knowledge-based)

4:30 PM – 5:45 PM
Integrated Omics in Heart Failure: Precision Medicine Highlights for Heart Failure Clinicians and Scientists
ACPE UAN: JA4008267-0000-20-025-H04-P
(1.25 contact hours – knowledge-based)

4:30 PM – 5:45 PM
The Intersection of Cardio-Oncology and Advanced HF: From Stage A to D
ACPE UAN: JA4008267-0000-20-026-H04-P
(1.25 contact hours – knowledge-based)

Monday, October 5, 2020

6:00 PM – 7:00 PM
Patient Pearls for Advanced HF: A View From the Other Side
ACPE UAN: JA4008267-0000-20-027-H04-P
(1.0 contact hours – knowledge-based)

7:15 PM – 8:15 PM
Navigating the Early Career Waters: Pearls for Achieving Success - What They Didn't Teach You in Training
ACPE UAN: JA4008267-0000-20-028-H04-P
(1.0 contact hours – knowledge-based)

Tuesday, October 6, 2020

6:00 PM – 7:00 PM
The Economics of HF – Exploring Social Determinants and Financial Burden in the Care of Patients with HF
ACPE UAN: JA4008267-0000-20-029-H04-P
(1.0 contact hours – knowledge-based)

6:00 PM – 7:00 PM
Dr. Alexa is In: Leveraging Technology in Heart Failure Care
ACPE UAN: JA4008267-0000-20-030-H04-P
(1.0 contact hours – knowledge-based)
CE Credit Information

Criteria for Successful Completion

Successful completion of this continuing education activity includes participation in the evaluation post course evaluation. For those session designated for MOC credits, participants must also achieve a passing score of 75% on the evaluation’s post-test.

See below for details on claiming credits while in the virtual meeting platform.

Claiming CE and MOC Credit in the Virtual Platform

Claiming CE Credits

To claim CE credit, access the “Claim CE Credit” link in the player during a scientific session for each session-specific evaluation.

- Evaluations must be completed in order to receive credit certificates.
- All evaluations will be electronic and are mobile optimized.
- Evaluations can be accessed during and following the meeting.

Learners are advised to access the “Claim CE Credit” tab during the session as the first option, but if the session has ended, learners may access CE Credit information and evaluations via this link: https://ceu.experientevent.com/HFS201

Claiming MOC Credits

To claim MOC, learners must complete the pre-test found in the “Session Info & Pre-Test” tab of the session player. At the conclusion of the course, learners must complete the evaluation, achieve a 75% passing score on the posttest assessment, and provide the HFSA with their ABIM ID# and DOB. (MM/DD)

The HFSA will report all successfully obtained MOC contact hours directly to the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Satellite Symposia Information

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Satellite symposia will each offer 1.25 hours of continuing education credit.

Please refer to the satellite handout materials for exact hours for physician credits and nursing credits (if applicable).
Following this meeting, attendees will be able to:

1. Describe the epidemiology of HF and implement strategies for the prevention of HF.
2. Discuss the current scientific basis of HF from the perspectives of cardiovascular physiology, neurohormones, tissue factors, molecular biology, and genetics.
3. Identify the findings of basic science research and current clinical trials and describe their implications for current and future HF therapy.
4. Implement optimal guideline-based therapeutic options for HF, including pharmacologic agents, non-pharmacologic options, such as diet and exercise; and implantable devices.
5. Manage comorbidities including hypertension, diabetes, depression, sleep apnea, and chemotherapy.
6. Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues in the treatment of patients with HF.
7. Explain the patient, provider and system-related factors that contribute to racial and ethnic health disparities.
8. Implement strategies for effective management of the patient with HF, incorporating the family, encouraging self-care, and employing the team approach.
9. Outline strategies for transitioning patients from inpatient to outpatient care and for reducing hospital readmissions.
10. Engage in performance measurement and other site-based research.

Specific learning objectives for each of the scientific sessions and satellite symposia are listed in the session description in the virtual meeting platform.

Competencies Addressed

The 2020 scientific program contains content that addresses the following ABMS core competencies:

- Patient care
- Medical knowledge
- Interpersonal and communications skills
- Professionalism
- Systems-based practice
- Sessions also address the following ABIM specified competency areas in advanced heart failure and transplant cardiology:
  - Epidemiology and risk factors
  - Pathophysiology of heart failure
  - Hemodynamics and hemodynamic monitoring
  - Heart failure and normal ejection fraction
  - Heart failure with renal dysfunction / cardiorenal syndrome
  - Diagnostic tests and procedures
  - Acute decompensation of chronic heart failure
  - Subset of patients with heart failure, including women, the elderly, and different racial or ethnic groups
  - Heart failure comorbidities
  - Heart failure and pregnancy
  - Cardiomyopathies
  - Pharmacotherapy
  - Implantable devices
  - Heart transplant
  - Mechanical circulator support
  - End-of-Life Issues
Presentation Information

Audience Response System

Instructions for Attendees:

During live presentations, attendees can click the “Interactivity” tab to submit questions for session faculty. If the session has live polling, it will also appear under this tab.

Meeting Content

The HFSA Virtual Annual Scientific Meeting 2020 provides a forum for the open exchange and discussion of research results and scientific advancements in the field of heart failure; however, HFSA makes no representation or warranty as to the truth, originality, or accuracy of the information presented. Nor are the views expressed by the individual speakers necessarily the view of HFSA. HFSA supports the ACCME’s policy on evidence-based content and requires faculty to adhere to these standards when preparing a presentation.

Presenter / Planner Disclosure Information

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speaker disclosure information is available in the virtual meeting platform Resources Hub. Speakers also have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the Joint Accreditation Updated Standards for Commercial Support.
Supporters

CE Satellite Symposium

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year’s Satellite Symposia.

Supported by independent educational grants from:
Akcea Therapeutics
Alnylam Pharmaceuticals
Amyloidosis Research Consortium
AstraZeneca
Boehringer-Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC
Eidos Therapeutics
Merck
Pfizer

Interactive Workshops

The Heart Failure Society of America acknowledges the following for providing an in-kind donation to support this year’s workshop:

Abbott
ActiCare
Medtronic
Eko Devices, Inc.
## Continuing Education Program

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, September 30, 2020</strong></td>
<td><strong>6:00 PM - 7:00 PM</strong></td>
<td><strong>SS / MOC / CPE / NPharm</strong> COVID-19: Lessons Learned in HF and Living with the New Normal</td>
<td>Scientific Session Theater A</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS / CPE / NPharm</strong> To Right A Wrong in HF</td>
<td>Scientific Session Theater B</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS</strong> Clinical Conundrums - Multidisciplinary Case Discussion</td>
<td>Scientific Session Theater C</td>
</tr>
<tr>
<td></td>
<td><strong>7:15 PM - 8:15 PM</strong></td>
<td><strong>SS / MOC / CPE / NPharm</strong> Beyond Socioeconomic &amp; Access To Care: The Clinical Imperative for Understanding Racial HF Differences and Disparities <em>(Joint Session ABC)</em></td>
<td>Scientific Session Theater A</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS / CPE / NPharm</strong> Heart Meets Kidney</td>
<td>Scientific Session Theater B</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS</strong> Future HF Trials</td>
<td>Scientific Session Theater C</td>
</tr>
<tr>
<td><strong>Thursday, October 1, 2020</strong></td>
<td><strong>4:30 PM - 5:45 PM</strong></td>
<td><strong>SAT</strong> Navigating the Evolving Paradigm in Heart Failure: The Emerging Impact of SGLT2 Inhibition (CEUs) <em>Supported through an independent educational grant from Astra Zeneca</em></td>
<td>Satellite Symposium Theater</td>
</tr>
<tr>
<td><strong>6:00 PM - 7:00 PM</strong></td>
<td></td>
<td><strong>SS / MOC / CPE</strong> Update on Medical Treatment Strategies in HF</td>
<td>Scientific Session Theater B</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS / CPE / NPharm</strong> Supporting the HF Workforce: Optimizing Physical and Mental Wellness Among HF Providers <em>(Joint Session w/AAHFN)</em></td>
<td>Scientific Session Theater C</td>
</tr>
<tr>
<td><strong>7:15 PM – 8:15 PM</strong></td>
<td></td>
<td><strong>SS / MOC / CPE / NPharm</strong> HF and the End of Life – Opportunities for Innovation and Collaboration at the Intersection of Cardiology and Palliative Care</td>
<td>Scientific Session Theater B</td>
</tr>
<tr>
<td><strong>Friday, October 2, 2020</strong></td>
<td><strong>4:30 PM - 5:45 PM</strong></td>
<td><strong>SAT</strong> HFrEF: Challenges, Unmet Needs and Emerging Therapies (CEUs) <em>Supported by an independent medical education grant from Merck</em></td>
<td>Satellite Symposium Theater</td>
</tr>
<tr>
<td><strong>6:00 PM - 7:00 PM</strong></td>
<td></td>
<td><strong>SS / CPE</strong> 2020 and Beyond: Background Medical Therapy for Clinical Trials <em>(FDA Special Session)</em></td>
<td>Scientific Session Theater A</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS MOC CPE</strong> Contemporary Challenges In Heart Transplantation: A New Decade, New Opportunities</td>
<td>Scientific Session Theater B</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SS / CPE / NPharm</strong> HF Hospitalizations and Transitions of Care: It Takes A Village</td>
<td>Scientific Session Theater C</td>
</tr>
</tbody>
</table>
### Continuing Education Program

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

<table>
<thead>
<tr>
<th><strong>KEY</strong></th>
<th><strong>SS</strong></th>
<th>Scientific Session</th>
<th><strong>SAT</strong></th>
<th>Satellite Symposium</th>
<th><strong>CPE</strong></th>
<th>Pharmacy Credits</th>
<th>MOC</th>
<th>MOC Session</th>
<th>NPHARM</th>
<th>Nursing Pharmacology Credits</th>
<th>IT</th>
<th>Industry Theater</th>
<th>NET</th>
<th>Networking</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Friday, October 2, 2020 - Continued</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:15 PM – 8:15 PM</strong></td>
</tr>
<tr>
<td><strong>SS</strong></td>
</tr>
<tr>
<td><strong>SS</strong></td>
</tr>
<tr>
<td><strong>SS</strong></td>
</tr>
<tr>
<td><strong>Saturday, October 3, 2020</strong></td>
</tr>
<tr>
<td><strong>10:00 AM – 11:00 AM</strong></td>
</tr>
<tr>
<td><strong>11:00 AM – 11:30 AM</strong></td>
</tr>
<tr>
<td><strong>11:45 AM – 1:15 PM</strong></td>
</tr>
<tr>
<td><strong>SS / CPE / NPharm</strong></td>
</tr>
<tr>
<td><strong>1:30 PM – 2:45 PM</strong></td>
</tr>
<tr>
<td><strong>3:00 PM – 4:15 PM</strong></td>
</tr>
<tr>
<td><strong>SS / CPE / NPharm</strong></td>
</tr>
<tr>
<td><strong>SS / NPharm</strong></td>
</tr>
<tr>
<td><strong>4:30 PM – 5:30 PM</strong></td>
</tr>
<tr>
<td><strong>SS / CPE / NPharm</strong></td>
</tr>
<tr>
<td><strong>SS / NPharm</strong></td>
</tr>
<tr>
<td><strong>6:00 PM – 7:00 PM</strong></td>
</tr>
<tr>
<td><strong>SS MOC CPE</strong></td>
</tr>
<tr>
<td><strong>SS / CPE / NPharm</strong></td>
</tr>
</tbody>
</table>
**Continuing Education Program**

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

<table>
<thead>
<tr>
<th>Key</th>
<th>SS</th>
<th>MOC</th>
<th>Sat</th>
<th>CPE</th>
<th>Pharmacy Credits</th>
<th>IT</th>
<th>NET</th>
<th>Networking</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Scientific Session</td>
<td>MOC Session</td>
<td>Satellite Symposium</td>
<td>Nursing Pharmacology Credits</td>
<td>Industry Theater</td>
<td>Networking</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Saturday, October 3, 2020 - Continued

**6:00 PM – 7:00 PM**

**SS / CPE**

Knowing it When you See it: Defining Congestion and Decongestion

Scientific Session Theater A

**SS / CPE**

When Social Determinants of Health Collide with HF Care and Treatment Decisions

Scientific Session Theater B

### Sunday, October 4, 2020

**10:00 AM – 11:30 AM**

**SS / NPHARM**

New Data and Learnings from VICTORIA Trial

Scientific Session Theater A

**SS**

INTERNATIONAL SESSION - Universal Definition of HF (Joint Session HFA / ESC / JHFS / CHFSA)

Scientific Session Theater B

**SS / MOC / CPE / NPHARM**

Cardiogenic Shock in 2020: Evolving Definitions, Devices, and Delivery

Scientific Session Theater C

**11:45 AM – 1:15 PM**

**SS / NPHARM**

DAPA-HF - One Year On

Scientific Session Theater A

**SS / CPE**

Women in HF Career Forum

Scientific Session Theater B

**SS / CPE / NPHARM**

Cardiac Cachexia: Mechanisms, Measuring Muscle, and Managing Malnutrition

Scientific Session Theater C

**1:30 PM - 2:45 PM**

**SAT**

Emerging Issues in Cardiac Amyloidosis: Moving from rare and fatal, to a treatable chronic cardiovascular disease (CEUs)

Supported by independent medical education grants from Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Eidos Therapeutics and the Amyloidosis Research Consortium

Satellite Symposium Theater

**SS / CPE / NPHARM**

Targeting Therapy for HFpEF

Scientific Session Theater A

**3:00 PM – 4:15 PM**

**SS**

WORKSHOP: Remote Monitoring for HF - Specialized Devices and ICDs

Supported by an in-kind donation from Abbott, ActiCare, Medtronic, Eko Devices, Inc.

Scientific Session Theater B

**SS / CPE**

Women and Gender Influences in HF

Scientific Session Theater C

**4:30 PM – 5:45 PM**

**SS / MOC / CPE / NPharm**

Understanding HF with Recovered Ejection Fraction

Scientific Session Theater A

**SS / CPE / NPharm**

Integrated Omics in HF: Precision Medicine Highlights for HF Clinicians and Scientists

Scientific Session Theater B

**SS / MOC / CPE / NPharm**

The Intersection of Cardio-Oncology and Advanced HF: From Stage A to D

Scientific Session Theater C

**6:00 PM – 7:00 PM**

**SS**

Atrial Fibrillation and HF: The Beat Goes On

Joint Session with Canadian HF Society (CHFS)

Scientific Session Theater A

**SS**

Implementation: Systematic Strategies of Improving Care and Outcomes

Scientific Session Theater B
## Continuing Education Program

This is the CE Program only. For a complete listing of all meeting activities please refer to the Meeting Program.

<table>
<thead>
<tr>
<th>KEY</th>
<th>Scientific Session</th>
<th>MOC</th>
<th>Satellite Symposium</th>
<th>CPE</th>
<th>Pharmacy Credits</th>
<th>NPHARM</th>
<th>Networking</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS</td>
<td>Scientific Session</td>
<td>MOC</td>
<td>Scientific Session</td>
<td>CPE</td>
<td>Pharmacy Credits</td>
<td>NPHARM</td>
<td>Networking</td>
</tr>
</tbody>
</table>

### Monday, October 5, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM – 7:00 PM</td>
<td>SS</td>
<td>Clinical-Pathological Cases (CPC): Stump the Professor</td>
</tr>
<tr>
<td></td>
<td>SS / CPE</td>
<td>Patient Pearls for Advanced HF: A View From the Other Side</td>
</tr>
<tr>
<td></td>
<td>SS / NPHARM</td>
<td>Late Breaking Clinical Trials II (LBCT)</td>
</tr>
<tr>
<td>7:15 PM – 8:15 PM</td>
<td>SS / CPE</td>
<td>Navigating the Early Career Waters: Pearls for Achieving Success - What They Didn’t Teach You in Training</td>
</tr>
<tr>
<td></td>
<td>SS</td>
<td>Paper-of-the-Year from Top HF Journals</td>
</tr>
</tbody>
</table>

### Tuesday, October 6, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM – 7:00 PM</td>
<td>SS</td>
<td>Management of the Medically Complex Patient (Workshop 2)</td>
</tr>
<tr>
<td></td>
<td>SS / MOC / CPE</td>
<td>The Economics of HF – Exploring Social Determinants and Financial Burden in the Care of Patients with HF</td>
</tr>
<tr>
<td></td>
<td>SS / CPE</td>
<td>Dr. Alexa is In: Leveraging Technology in Heart Failure Care</td>
</tr>
<tr>
<td>7:15 PM – 8:15 PM</td>
<td>SS</td>
<td>Research Network Update (No- CEUs)</td>
</tr>
<tr>
<td></td>
<td>SS</td>
<td>TEACH Workshop (Joint Workshop CRF)</td>
</tr>
</tbody>
</table>
2020 Exhibitors

**Exhibit Hall A – Commercial**

**Patron**
Cytokinetics, Inc.
Novartis Pharmaceuticals Corporation

**VIP**
Abbott
Akcea Therapeutics
Alnylam Pharmaceuticals (Commercial)
Amgen Inc.

**Premium**
Abiomed
Boehringer Ingelheim Pharmaceuticals, Inc. / Lilly USA
CMP Pharma
Eidos Therapeutics
Impulse Dynamics USA, Inc.
Medtronic
Pfizer
scPharmaceuticals

**Benefactor**
CVRx
Getinge
Merck & Co. Inc.

**Enhanced**
AstraZeneca Pharmaceuticals
Boston Scientific
MyoKardia, Inc.
Pfizer

**Basic**
American College of Cardiology
American Heart Association
CareDX Inc.
CHF Solutions
Daxor
Endotronix
ImpediMed Inc.
Respicardia, Inc.
TandemLife | LivaNova

**Exhibit Hall B – Medical**

**Patron**
Novartis Pharmaceuticals Corporation

**VIP**
Alnylam Pharmaceuticals (Medical)
Amgen Inc.

**Enhanced**
Relypsa, Inc, a Vifor Pharma Company